Accepted Manuscript

Accepted Manuscript (Uncorrected Proof)

Title: COVID 19 and Allergy in Pediatrics

Authors: Javad Ghaffari1,*

1Professor in Allergy and Clinical Immunology, Mazandaran University of Medical Sciences, Sari, Iran.

Corresponding author: Email: javadneg@yahoo.com, jghaffari94@gmail.com

To appear in: Journal of Pediatrics Review

Received date: 2020/10/14
Revised date: 2020/10/16
Accepted date: 2020/10/18

This is a “Just Accepted” manuscript, which has been examined by the peer-review process and has been accepted for publication. A “Just Accepted” manuscript is published online shortly after its acceptance, which is prior to technical editing and formatting and author proofing. Journal of Pediatrics Review provides “Just Accepted” as an optional and free service which allows authors to make their results available to the research community as soon as possible after acceptance. After a manuscript has been technically edited and formatted, it will be removed from the “Just Accepted” web site and published as a published article. Please note that technical editing may introduce minor changes to the manuscript text and/or graphics which may affect the content and all legal disclaimers that apply to the journal pertain.

Please cite this article as:

Letter to the Editor

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus and highly contagious that affects all age groups such as children. Any age, including infancy, could be affected by the pandemic. More than 210 countries have been affected by now. Clinical manifestations are variable (asymptomatic to severe pneumonia) in children (1). Allergic diseases are common and increasing all over the world. Asthma is the most common non-communicable allergic disease among children (2).

There was no difference between allergic and non-allergic COVID-19 among children in the incidence, clinical features, and laboratory and immunological findings. Allergy was not a risk factor for developing and severity of SARS-CoV-2 infection and hardly influence the COVID-19 disease course in children (1). Allergic conditions are not an increased risk factor for severe diseases and usually show a mild course. However, severe or uncontrolled asthma is an increased risk of developing more severe COVID-19 (3-5). Patients with allergic disorders such as asthma, allergic rhinitis, and atopic dermatitis should be continuing their prescribed drugs such as inhaled and intranasal corticosteroid, long-acting bronchodilators, and anti-leukotriene drugs (even oral corticosteroids) (3-5).

Biological drugs could be continuing exception during the acute phase of COVID-19 infection. Spirometry should be avoided in patients with confirmed or suspected cases of COVID-19. In special conditions with the use of a disposable filter, instrument sterilization, and personal protective equipment, spirometry can be done (5, 6). Sublingual and subcutaneous immunotherapy can be continued in asymptomatic patients, negative real-time PCR (RT-PCR), or after adequate quarantine. They should be discontinued in symptomatic or positive RT-PCR COVID 19 (7). The main treatment of COVID 19 is supportive care and no vaccines or specific antiviral treatments are available so far (8,9). The World Health Organization (WHO) and the European Centre for Disease Control (ECDC) recommended continuing treatment of other diseases according to guidelines in patients at risk or affected by COVID-19. Of course, there should not be interference with treatment with COVID-19 or vice versa (10).

Footnotes

Conflict of Interests: None declared.

Funding/Support: None.
References


